Zenas BioPharma, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $1Mn |
Net Profits | $-111.46Mn |
Net Profit Margins | -11145.6% |
Zenas BioPharma, Inc. Common Stock’s revenue jumped +Inf% since last year same period to $1Mn in the Q2 2026. On a quarterly growth basis, Zenas BioPharma, Inc. Common Stock has generated +Inf% jump in its revenue since last 3-months.
Zenas BioPharma, Inc. Common Stock’s net profit fell -113.42% since last year same period to $-111.46Mn in the Q2 2026. On a quarterly growth basis, Zenas BioPharma, Inc. Common Stock has generated -37.62% fall in its net profits since last 3-months.
Zenas BioPharma, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -11145.6% in the Q2 2026. On a quarterly growth basis, Zenas BioPharma, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.89 |
EPS Estimate Current Year | -0.89 |
Zenas BioPharma, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.89 - a 42.21% jump from last quarter’s estimates.
Zenas BioPharma, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.89.
Key Ratios
Earning Per Share (EPS) | -1.77 |
Zenas BioPharma, Inc. Common Stock’s earning per share (EPS) fell -41.6% since last year same period to -1.77 in the Q2 2026. This indicates that the Zenas BioPharma, Inc. Common Stock has generated -41.6% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-13 | -1.54 | -1.46 | 5.19% |
2026-08-13 | -0.89 | -1.77 | -98.88% |
